Theravance Biopharma (NASDAQ:TBPH) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a research note issued to investors on Thursday.

Other research analysts have also issued reports about the company. BTIG Research assumed coverage on Theravance Biopharma in a research report on Friday, April 12th. They set a buy rating and a $21.00 price target for the company. HC Wainwright restated a buy rating and set a $20.00 price target on shares of Theravance Biopharma in a research report on Wednesday, May 29th.

Theravance Biopharma Price Performance

TBPH stock opened at $9.33 on Thursday. The business has a fifty day moving average of $8.83 and a two-hundred day moving average of $9.20. Theravance Biopharma has a 52-week low of $8.13 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $14.54 million. Sell-side analysts forecast that Theravance Biopharma will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TBPH. China Universal Asset Management Co. Ltd. boosted its holdings in Theravance Biopharma by 324.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 4,402 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Theravance Biopharma by 31.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,227 shares during the period. Gerber LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at $112,000. Simplicity Solutions LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at $141,000. Finally, Bleakley Financial Group LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at $141,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.